Solid Tumors

**VAR0176**
Phase II
Nivolumab +/- ipilimumab
According to % of Tumoral CD8 Cells in Advanced Metastatic Cancer
PI: Kummar Parker Institute

**VAR0175**
Phase I
Intratumoral Injection of SD-101 +/- BMS-986175 in Advanced Solid Malignancies
PI: Kummar Stanford

**VAR0197**
Phase III
17Lu-38P-227 in Solid Tumors Expressing Neurotensin Receptor Type 1
PI: Aparici Pending

**VAR0185**
Phase Ib
Nivolumab in Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
PI: Kummar NCI

**VAR0180**
Phase II
ASTX029 in Advanced Solid Tumors
PI: Kummar Pending

**VAR0186**
Phase II
Pemigatinib in Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations
PI: Kummar Pending

**VAR0191**
Phase III
MCLA-128 a Full Length IgG1 Bispecific Antibody Targeting HER2 & HER3 in Solid Tumors
PI: Kummar Merus

**VAR0152**
Phase III of EDO-S101 in Advanced Solid Tumors
PI: Kummar Pending

**VAR0154**
Phase III
TRK Inhibitor LOXO-195 in Adult and Pediatric Previously Treated NTRK Fusion Cancers
PI: Kummar Loxo Oncology

**VAR0181**
Phase I/IIa
17Lu-NeoB in Advanced Solid Tumors Known in Preactivin GastriReleasing Peptide Receptor
PI: Kummar Advanced Accelerator Applications SA